

Pr JAMP Lenalidomide

Reference product REVLIMID® (Celgene)



Available through the RevAid
Controlled Distribution Program



Pills shown are not
actual size

| | | |
|-------------------------------|---|-------------------|
| Therapeutic Use | Antineoplastic and immunomodulating agent | |
| Indication¹ | <ul style="list-style-type: none"> Indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant. | |
| Active Ingredient | Lenalidomide | |
| DOSAGE STRENGTHS | DIN | SUPPLIED |
| 2.5 mg | 02506130 | 21 count blisters |
| 5 mg | 02506149 | 28 count blisters |
| 10 mg | 02506157 | 28 count blisters |
| 15 mg | 02506165 | 21 count blisters |
| 20 mg | 02506173 | 21 count blisters |
| 25 mg | 02506181 | 21 count blisters |
| Storage and handling | Store at 15-30°C. Health care providers may consider wearing gloves when directly handling chemotherapeutic agents such as lenalidomide capsules | |
| Shelf Life | 36 months | |

Consult the Product Monograph at www.jampinfo.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

This document contains information only for residents of Canada. Please be aware that JAMP PHARMA CORPORATION assumes no responsibility for access to and use of such information which may not comply with legal restrictions, regulations, registrations or intended use in the country if your origin. Eligibility restrictions and other terms and conditions may apply

Reference: 1. JAMP Lenalidomide Product Monograph. JAMP Pharma Corporation, October 2, 2020.



The JAMP Care™ Patient Support Program

Provides the following benefits to your patients taking



Available through the RevAid Risk Management Plan

Pr JAMP Lenalidomide



Reimbursement Navigation



Blood/Laboratory Work & Coordination



Bridging (as per provincial regulations)



Compassionate Use/Care Supply*



Financial Assistance (as per provincial regulations)



Personalized Consultation with a Nutritionist (available on demand)

PLUS

| JAMP Lenalidomide | JAMP CARE™ | Other Programs |
|---|------------|----------------|
| Reimbursement Navigation | ✓ | ✓ |
| Bridging | ✓ | ✓ |
| Financial Assistance | ✓ | ✓ |
| Blood/ Laboratory Work & Coordination | ✓ | ✓ |
| Compassionate Use/Care Supply* | ✓ | ✓ |
| Personalized Consultation with Nutritionist (available on demand) | ✓ | |

*Terms and conditions apply

For more information on the JAMP Care Patient Support Program



Call toll-free: 1-855-310-5102
Monday to Friday, 8am to 8pm EST



Email: jampcare@supportprogram.com



Visit: www.jampcare-support.ca

For specific questions about JAMP Lenalidomide:



Call the JAMP Pharma Group Medical Information Department at 1-866-399-9091 Option 2



Email at medinfo@jamppharma.com

Consult the Product Monograph at www.jampinfo.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

Reference: 1. JAMP Lenalidomide Product Monograph. JAMP Pharma Corporation, October 2, 2020.